15 unchanged sentences
Changes in Internal Control over Financial Reporting
−Removed: Except as noted above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the fourth quarter of our fiscal year ended December 31, 2024.
+Added: There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the fourth quarter of our fiscal year ended December 31, 2025.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
158 unchanged sentences
Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc.
+Added: 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.10l to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-14027) filed on March 17, 2025)
+Added: Form of Notice of Grant of Strategic Phantom Performance Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under the Anika Therapeutics, Inc.
+Added: 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1a to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-14027) filed on May 9, 2025)
+Added: Form of Notice of Grant of Market Phantom Performance Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under the Anika Therapeutics, Inc.
+Added: 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1b to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-14027) filed on May 9, 2025)
+Added: Form of Notice of Grant of Stock Appreciation Rights, including Terms and Conditions of Stock Appreciation Rights, granted under the Anika Therapeutics, Inc.
2017 Omnibus Incentive Plan
6 unchanged sentences
Executive Retention Agreement, dated December 12, 2024, by and between Anika Therapeutics, Inc.
−Removed: and David Colleran
+Added: and David Colleran (incorporated by reference to Exhibit 10.13 to the Registrant’ s Annual Report on Form 10-K (File No.
+Added: 001-14027) filed on March 17, 2025)
Executive Retention Agreement, dated September 27, 2021, by and between Anika Therapeutics, Inc.
2 unchanged sentences
Executive Retention Agreement, dated December 12, 2024, by and between Anika Therapeutics, Inc.
−Removed: and Steve Griffin
+Added: and Steve Griffin (incorporated by reference to Exhibit 10.15 to the Registrant’ s Annual Report on Form 10-K (File No.
+Added: 001-14027) filed on March 17, 2025)
Cooperation Agreement, dated May 28, 2024, by and among Anika Therapeutics, Inc.
7 unchanged sentences
001-14027) filed by the Registrant on May 8, 2024)
−Removed: Restated Insider Trading Policy
+Added: Transitional Services and Separation Agreement, dated January 7, 2026, by and among Anika Therapeutics, Inc.
+Added: and Cheryl R.
+Added: Blanchard (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No.
+Added: 001-14027) filed by the Registrant on January 7, 2026)
+Added: Employment Agreement, dated January 7, 2026, by and among Anika Therapeutics, Inc.
+Added: and Stephen Griffin (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No.
+Added: 001-14027) filed by the Registrant on January 7, 2026)
+Added: Restated Insider Trading Policy (incorporated by reference to Exhibit 19 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-14027) filed on March 17, 2025)
List of Subsidiaries of Anika Therapeutics, Inc.
Consent of Deloitte & Touche LLP
−Removed: Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification pursuant to 18 U.S.C.
24 unchanged sentences
March 2, 2026
−Removed: /s/ CHERYL BLANCHARD
−Removed: Blanchard, Ph.D.
+Added: /s/ STEPHEN GRIFFIN
+Added: Stephen Griffin
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
−Removed: /s/ CHERYL BLANCHARD
−Removed: President and Chief Executive Officer
−Removed: Blanchard, Ph.D.
−Removed: ( Principle Executive Officer )
−Removed: March 14, 2025
/s/ STEPHEN GRIFFIN
−Removed: Executive Vice President, Chief Financial Officer and Treasurer
+Added: President and Chief Executive Officer
Stephen Griffin
−Removed: (Principal Financial Officer)
+Added: ( Principle Executive Officer and Principal Financial Officer )
March 2, 2026
3 unchanged sentences
March 2, 2026
−Removed: HENNEMAN, III
−Removed: Director, Chairman of the Board
+Added: /s/ CHERYL BLANCHARD
+Added: Director, Executive Chair of the Board
March 2, 2026
−Removed: Henneman, III
+Added: Blanchard, Ph.D.
/s/ JOSEPH H.
3 unchanged sentences
March 2, 2026
+Added: HENNEMAN, III
+Added: Lead Director
+Added: March 2, 2026
+Added: Henneman, III
/s/ WILLIAM R.
5 unchanged sentences
March 2, 2026
−Removed: /s/ SUSAN L.N.
−Removed: March 14, 2025
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.